Supplementary Figures 1 - 11 from Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

PDF file - 4999K, Supplementary Figure S1. Characterization of lymphatic vessels in non-reactive lymph nodes and mantle cell lymphoma xenografts. Supplementary Figure S2. LEN treatment decreases MCL dissemination. Supplementary Figure S3. LEN treatment does not affect the function of pre-existing host collecting lymphatic vessels. Supplementary Figure S4. Disseminated MCL tumor cells are within the lymphatic vessels in the distant axillary lymph nodes. Supplementary Figure S5. LEN treatment does not affect the proliferation, survival, or migration of lymphatic endothelial cells in vitro. Supplementary Figure S6. Gene expression profiles of lymphatic endothelial cells, macrophages and MCL xenografts after LEN treatment. Supplementary Figure S7. LEN treatment decreases macrophages in tumor peripheral regions. Supplementary Figure S8. LEN treatment does not affect the proliferation, survival, migration or VEGF-C expression of macrophages in vitro. Supplementary Figure S9. Clodrolip treatment results in significant macrophage depletion at tumor peripheral regions. Supplementary Figure S10. Tumor lymphangiogenesis is affected at early stage after LEN treatment. Supplementary Figure S11. LEN treatment inhibits functional angiogenesis.